News & Updates

The pan-sarbecovirus monoclonal antibody sotrovimab appears to reduce the risk of COVID-19 disease progression in high-risk patients, according to interim results of the phase III COMET-ICE* trial.

In post hoc analyses of the phase III SINUS-24 and SINUS-52 trials, the monoclonal antibody dupilumab continued to render improvements for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), as well as among those with comorbid asthma regardless of asthma characteristics.

Secondary analysis of the DARE-19* trial presented at ASN Kidney Week 2021 has shown that the effect of dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 is consistent regardless of kidney disease status.

New research suggests that COVID toe – a form of COVID-19–associated pernio or chilblains – may be a side effect of the immune system's response to fighting off the virus.

Small airway disfunction can lead to increased airway resistance and visible computed tomography (CT) changes, according to a study. Furthermore, this disease is more common among individuals with advanced age, high body mass index (BMI), childhood cough, and asthma.

Expectant mothers with symptomatic COVID-19 upon hospital admission for delivery had a higher risk of emergency complications surrounding delivery, according to a small retrospective study from the US presented at Anesthesiology 2021. Furthermore, infants born to symptomatic mothers were more likely to require intensive care unit (ICU) admission or respiratory support.